1. Indications and Usage
\nChronic Heart Failure (HF): Indicated for the treatment of adult patients with symptomatic chronic heart failure and a left ventricular ejection fraction (LVEF) of less than 45%.
\nIt is used to reduce the risk of cardiovascular death and hospitalization for heart failure.
\nIt is applicable to adult patients with symptomatic chronic heart failure who have recently experienced decompensated heart failure and have a stable condition after intravenous treatment with reduced ejection fraction (LVEF <45%), in order to reduce the risk of hospitalization for heart failure or the need for emergency intravenous diuretic treatment.
\n2. Dosage and Administration
\nAdministration: Oral administration. Must be taken with food to ensure adequate absorption (bioavailability) .
\nStarting Dose: 2.5 mg once daily.
\nTitration: Increase the dose approximately every 2 weeks based on tolerability (blood pressure and clinical status) to the target maintenance dose.
\nTarget Maintenance Dose: 10 mg once daily.
\nMissed Dose: Take as soon as possible on the same day with food. Do not take two doses on the same day. If a dose is missed, resume the normal schedule the next day.
\nSwallowing: Tablets may be crushed and mixed with water for patients who have difficulty swallowing .
\n3. Mechanism of Action
\nsGC Stimulator: Vericiguat is a soluble guanylate cyclase (sGC) stimulator.
\nPathway: It directly stimulates sGC, independent of nitric oxide (NO), and also sensitizes sGC to endogenous NO. This leads to an increase in intracellular cyclic guanosine monophosphate (cGMP) levels.
\nEffect: Increased cGMP results in smooth muscle relaxation and vasodilation, as well as inhibition of vascular smooth muscle cell proliferation and hypertrophy .
\n4. Safety and Warnings
\nHypotension: Symptomatic hypotension may occur. Monitor blood pressure, especially during dose titration. Not recommended for use with long-acting nitrates or PDE-5 inhibitors due to additive hypotensive effects \u3002
\nEmbryo-Fetal Toxicity: Vericiguat may cause fetal harm. It is contraindicated in pregnancy. Women of childbearing potential must use effective contraception during treatment and for at least one month after the last dose \u3002
\nContraindications:
\nPregnancy.
\nConcomitant use with other sGC stimulators (e.g., riociguat, priciguat) .
\n5. Adverse Reactions
\nMost Common (\u22655%): Hypotension and Anaemia .
\nOther Common Reactions: Dizziness, Headache, Nausea, Dyspepsia, Vomiting .
\n6. Drug Interactions
\nsGC Stimulators: Contraindicated with other sGC stimulators .
\nPDE-5 Inhibitors: Not recommended for concomitant use (e.g., sildenafil, tadalafil) due to the risk of severe hypotension \u3002
\nLong-acting Nitrates: Not recommended for concomitant use .
\n7. Pharmaceutical Information
\nChemical Name: Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzoyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate .
\nMolecular Formula: C19H16FN5O3 .
\nStorage: Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F). Keep container tightly closed .<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u552f\u53ef\u540c \u00ae(Verquvo\u00ae)
\nGeneric Name: Vericiguat
\nStrength: 5 mg per film-coated tablet, 7 tablets per box
\nManufacturer: Bayer AG
\nMarketing Authorization Holder: Bayer AG\uff1b\u5883\u5185\u8d23\u4efb\u4eba\uff1a\u62dc\u8033\u533b\u836f\u4fdd\u5065\u6709\u9650\u516c\u53f8
\nApproval Date in China: May 18, 2022
\nRegistration Number: \u56fd\u836f\u51c6\u5b57HJ20220051
\nStorage: Seal tightly, store at temperature not exceeding 30\u2103; the controlled storage temperature is 20\u2103\u201325\u2103, short-term fluctuation between 15\u2103\u201330\u2103 is acceptable; protect from light and moisture, keep out of sight and reach of children<\/p>\n
Price&Cost:Contact Us now for the best price of Vericiguat\uff08Verquvo\uff09<\/p>\n","protected":false},"featured_media":3051,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[86],"product_cat":[27],"product_tag":[],"class_list":["post-3050","product","type-product","status-publish","has-post-thumbnail","product_brand-bayer","product_cat-tablets","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n